See more : Sichuan Guoguang Agrochemical Co., Ltd. (002749.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Cresco Labs Inc. (CRLBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cresco Labs Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Pan African Resources PLC (PAF.L) Income Statement Analysis – Financial Results
- Gantan Beauty Industry Co., Ltd. (5935.T) Income Statement Analysis – Financial Results
- Safeguard Scientifics, Inc. (SFE) Income Statement Analysis – Financial Results
- MAG Interactive AB (publ) (MAGI.ST) Income Statement Analysis – Financial Results
- Koninklijke KPN N.V. (KKPNF) Income Statement Analysis – Financial Results
Cresco Labs Inc. (CRLBF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.crescolabs.com
About Cresco Labs Inc.
Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand, as well as cannabis products under the Reserve brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections, fruit-forward gummies, hard sweets, and taffy under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. As of January 27, 2022, it owned and operated 48 dispensaries. The company was founded in 2013 and is headquartered in Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 770.89M | 842.68M | 821.68M | 476.25M | 128.53M | 43.25M | 10.31M | 3.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 441.00M | 435.67M | 415.34M | 192.31M | 64.45M | 2.84M | 9.16M | 14.57 | 61.11 | 82.81 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 329.89M | 407.01M | 406.35M | 283.94M | 64.08M | 40.42M | 1.15M | 3.16M | -61.11 | -82.81 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 42.79% | 48.30% | 49.45% | 59.62% | 49.86% | 93.45% | 11.17% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 1.99M | 370.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 36.81M | 54.99M | 40.34M | 160.94M | 77.15M | 29.16M | 44.42K | 42.84K | 49.32K | 49.32K | 205.78K | 341.29K | 311.56K | 338.34K | 439.16K | 300.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 8.30M | 15.58M | 29.73M | 19.03M | 12.63M | 2.05M | 455.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.45K | 8.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 31.81K | 16.46K |
| SG&A | 259.81M | 350.65M | 317.80M | 179.97M | 89.78M | 31.21M | 44.42K | 42.84K | 49.32K | 49.32K | 205.78K | 341.29K | 311.56K | 338.34K | 440.60K | 308.96K | 673.66K | 442.67K | 1.56M | 437.22K | 244.28K | 130.92K | 45.36K | 31.81K | 16.46K |
| Other Expenses | 151.02M | -572.00K | 753.00K | 48.13M | 8.56M | 27.00K | 663.85 | 9.23K | 9.91K | 9.09K | 53.77K | 70.09K | 227.95K | 253.46K | 22.40K | -303.78K | 1.07K | 21.70K | 766.91 | 1.16K | -119.15K | 127.65K | 209.13K | 319.18K | 231.94K |
| Operating Expenses | 435.36M | 350.08M | 318.56M | 228.10M | 98.34M | 33.82M | 44.42K | 42.86K | -55.99K | 60.27K | 208.32K | 380.51K | 339.52K | 338.89K | 440.98K | 310.51K | 674.73K | 444.15K | 1.56M | 441.25K | 244.28K | 130.92K | 89.48K | 350.99K | 248.41K |
| Cost & Expenses | 858.71M | 785.75M | 733.89M | 420.41M | 162.79M | 36.65M | 44.42K | 42.86K | -55.99K | 60.27K | 208.32K | 380.51K | 339.52K | 338.89K | 440.98K | 310.51K | 674.73K | 444.15K | 1.56M | 441.25K | 244.28K | 130.92K | 89.48K | 350.99K | 248.41K |
| Interest Income | 2.42M | 679.00K | 938.00K | 1.41M | 1.58M | 89.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.96K | 18.40K | 0.00 | 1.56K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 63.24M | 58.52M | 52.15M | 40.91M | 9.46M | 89.00K | 41.60K | 30.81K | 26.49K | 33.62K | 48.18K | 39.92K | 39.75K | 49.55K | 32.63K | 3.78K | 0.00 | 1.10M | 0.00 | 0.00 | 182.35K | 0.00 | 0.00 | 132.58K | 0.69 |
| Depreciation & Amortization | 70.57M | 55.44M | 44.55M | 38.70M | 12.19M | 2.17M | 646.00K | 14.57 | 61.53 | 82.48 | 116.50 | 158.61 | 194.51 | 542.64 | 374.50 | 1.55K | 1.07K | 1.49K | 766.91 | 1.61 | 126.41K | 1.31 | 44.13K | 46.75K | 34.57K |
| EBITDA | -14.62M | -10.24M | -157.04M | 6.75M | -30.09M | 9.66M | -3.48M | -33.61K | 73.43K | -84.07K | -154.56K | -322.46K | 4.52K | -2.23M | -2.88M | -2.03M | -559.24K | -979.09K | -1.56M | -441.25K | -181.08K | -130.92K | -31.58K | -304.24K | -213.84K |
| EBITDA Ratio | -1.90% | 14.65% | 16.18% | 20.65% | -13.77% | 23.84% | -0.42% | -1.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -87.82M | 65.75M | 87.97M | 58.31M | -34.26M | 4.95M | -44.42K | -33.63K | 65.89K | -51.18K | -154.55K | -310.43K | -379.27K | -388.43K | -473.61K | -595.88K | -674.73K | -1.00M | -1.56M | -441.25K | -307.49K | -130.92K | -103.26K | -350.99K | -248.41K |
| Operating Income Ratio | -11.39% | 7.80% | 10.71% | 12.24% | -26.65% | 11.43% | -0.43% | -1.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -59.08M | -42.61M | -39.38M | -40.71M | -28.95M | -1.29M | 139.77K | 53.05K | 96.42K | -56.92K | 5.59K | 20.51K | 186.63K | -1.89M | -2.44M | -1.72M | 90.18K | -537.39K | 43.16K | 1.16K | -182.35K | 127.65K | 195.35K | -132.58K | -0.69 |
| Income Before Tax | -146.90M | -126.91M | -256.73M | 7.16M | -50.84M | 7.47M | -85.35K | -108.03K | 47.38K | -117.44K | -202.74K | -361.38K | -151.32K | -85.43K | -2.91M | -2.05M | -584.55K | -981.24K | -1.51M | -440.09K | -489.85K | -3.27K | 92.09K | -483.57K | -248.41K |
| Income Before Tax Ratio | -19.06% | -15.06% | -31.24% | 1.50% | -39.55% | 17.26% | -0.83% | -3.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 32.95M | 88.94M | 40.11M | 43.72M | 14.46M | 4.37M | -663.85 | 43.59K | -7.98K | 32.64K | 0.00 | 11.03K | -342.40K | 4.03M | 2.47M | -19.39K | -90.18K | 1.10M | -146.31K | -3.00K | 131.48K | -116.13K | -158.23K | 132.58K | 0.69 |
| Net Income | -175.52M | -215.84M | -296.83M | -36.56M | -65.30M | -1.92M | -85.35K | -108.03K | 47.38K | -117.44K | -202.74K | -361.38K | -36.87K | -2.28M | -2.91M | -2.03M | -584.55K | -981.24K | -1.37M | -438.25K | -438.97K | -14.79K | 82.52K | -483.57K | -248.41K |
| Net Income Ratio | -22.77% | -25.61% | -36.13% | -7.68% | -50.81% | -4.43% | -0.83% | -3.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.54 | -0.72 | -1.13 | -0.17 | -0.55 | -0.03 | -2.45 | -3.10 | 1.16 | -3.38 | -5.82 | -10.38 | -1.11 | -77.44 | -108.25 | -78.24 | -24.14 | -44.38 | -71.04 | -29.14 | -43.91 | -1.76 | 15.37 | -86.80 | -67.23 |
| EPS Diluted | -0.54 | -0.72 | -1.13 | -0.17 | -0.55 | -0.03 | -2.45 | -3.10 | 1.16 | -3.37 | -5.82 | -10.38 | -1.11 | -77.44 | -108.25 | -78.24 | -24.14 | -44.38 | -71.04 | -29.14 | -43.91 | -1.76 | 15.37 | -86.80 | -67.23 |
| Weighted Avg Shares Out | 323.82M | 298.16M | 262.33M | 210.47M | 118.32M | 59.34M | 34.79K | 34.79K | 34.79K | 34.79K | 34.81K | 34.81K | 33.17K | 29.39K | 26.89K | 25.89K | 24.21K | 22.11K | 19.24K | 15.04K | 10.00K | 8.38K | 6.21K | 5.57K | 3.70K |
| Weighted Avg Shares Out (Dil) | 323.82M | 298.16M | 262.33M | 210.47M | 118.32M | 59.34M | 34.81K | 34.81K | 34.81K | 34.81K | 34.81K | 34.81K | 33.17K | 29.39K | 26.89K | 25.89K | 24.21K | 22.11K | 19.24K | 15.04K | 10.00K | 8.38K | 6.21K | 5.57K | 3.70K |
Cresco Labs Inc. (CRLBF) Q1 2024 Earnings Call Transcript
Cresco Labs Inc. (OTCQX:CRLBF) Q1 2024 Earnings Conference Call May 15, 2024 8:30 AM ET Company Participants TJ Cole – Senior Vice President, Corporate Development and Investor Relations Charles Bachtell – Co-Founder and Chief Executive Officer Dennis Olis – Chief...
3 Marijuana Stocks To Buy While Cannabis Politics Are Ramped?
Marijuana stock investors are looking for any upside in this volatile time. Many of those who have been investing in cannabis stocks understand how tough it can be to see consistent momentum. For a long while, only news on federal...
U.S. cannabis dispensary operator Cresco Labs posts narrower loss as revenue dips
Cresco Labs Inc. CRLBF, +0.50% said Wednesday its first-quarter loss narrowed to $2.06 million, from $27.8 million in the year-ago quarter. Excluding taxes, first-quarter net income totaled $16 million, the company said.
Cresco Labs Reports Continued Trend of Financial Improvement with First Quarter 2024 Financial Results
CHICAGO--(BUSINESS WIRE)--Cresco Labs Reports Continued Trend of Financial Improvement with First Quarter 2024 Financial Results.
This Is How Marijuana Stocks Will Be Impacted By Reform In 2024
As the cannabis industry continues its growth in 2024, a confluence of regulatory, demographic, and market trends is shaping the sector. This has presented a fertile ground for savvy investors. Here's a deeper look into the evolving landscape of cannabis...
Shhh! 3 Secret Penny Stocks Flying Below Wall Street's Radar
Under-the-radar penny stocks can be some of the most rewarding investments on the market. Look at ACADIA Pharmaceuticals (NASDAQ: ACAD ), for example.
The 7 Top-Selling Cannabis Companies Ranked by Revenue: Which Weed Stocks to Buy?
Whispers and rumors of widespread cannabis legalization are growing louder. Although the last major surge in top cannabis stocks during the late 2010s significantly eclipses today's market and per-share pricing, top cannabis stocks are gradually ticking upward.
Will Cresco Labs Inc. (CRLBF) Report Negative Earnings Next Week? What You Should Know
Cresco Labs Inc. (CRLBF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Cresco Labs (CRLBF) is Placed Before Q1 Earnings
Cresco Labs' (CRLBF) rationalization and optimization efforts are expected to have had a positive impact on the company's first-quarter margins, profitability and cash flow.
Wall Street Analysts Predict 1000% Upside for These 7 Penny Stocks
The Federal Reserve just threw a wet blanket on small-cap stocks in general and penny stocks in particular in announcing that interest rates are not likely to come down soon. It's a time when “buy the best forget the rest”...
Source: https://incomestatements.info
Category: Stock Reports